Want to see IRD full AI Analyst Report?
Top Page
Opus Genetics
(NASDAQ:IRD)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.00
▼(-47.83% Downside)
Action:Reiterated
Date:06/17/26
The score is held down primarily by weak financial performance (declining revenue, large losses, negative equity, and ongoing cash burn) and bearish technical momentum (below key moving averages with negative MACD). Positive corporate developments around pipeline advancement and new financing improve near-term flexibility, but do not fully offset the current financial and trend risks.
Positive Factors
Broad gene‑therapy pipeline advancing to clinic
Opus runs a multi‑program IRD gene‑therapy portfolio with multiple candidates scheduled for clinical starts through 2027. A diversified pipeline increases the likelihood of technical or commercial success, creates multiple milestone catalysts, and spreads development risk across indications and geographies.
Negative Factors
Negative stockholders' equity
Cumulative losses that drive equity negative materially weaken the company’s balance sheet cushion, limit flexibility for absorbing setbacks, and raise the urgency of external financing. Negative equity is a structural constraint that can affect counterparties, partnering and long‑term solvency perceptions.
Read all positive and negative factors
Positive Factors
Negative Factors
Broad gene‑therapy pipeline advancing to clinic
Opus runs a multi‑program IRD gene‑therapy portfolio with multiple candidates scheduled for clinical starts through 2027. A diversified pipeline increases the likelihood of technical or commercial success, creates multiple milestone catalysts, and spreads development risk across indications and geographies.
Read all positive factors
Opus Genetics (IRD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$269.99M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)0.61
Revenue Growth-12.22%
EPS Growth30.28%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.31
Shares Outstanding82,565,834
10 Day Avg. Volume828,922
30 Day Avg. Volume1,029,967
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.14Price Target Upside93.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$15.91M
Opus Genetics Business Overview & Revenue Model
Company Description
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refr...
How the Company Makes Money
null...
Opus Genetics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.98M | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| Gross Profit | 5.95M | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| EBITDA | -104.73M | -48.07M | -57.52M | -9.97M | 18.22M | -56.69M |
| Net Income | -106.93M | -49.59M | -57.53M | -9.99M | 17.89M | -56.69M |
Balance Sheet | ||||||
| Total Assets | 66.79M | 50.24M | 36.86M | 53.95M | 48.99M | 26.08M |
| Cash, Cash Equivalents and Short-Term Investments | 59.96M | 45.09M | 30.32M | 50.52M | 42.68M | 24.75M |
| Total Debt | 25.93M | 0.00 | 0.00 | 0.00 | 0.00 | 538.00K |
| Total Liabilities | 112.62M | 34.90M | 30.14M | 4.04M | 2.75M | 3.85M |
| Stockholders Equity | -45.84M | 15.35M | 6.72M | 49.91M | 46.24M | 22.22M |
Cash Flow | ||||||
| Free Cash Flow | -38.99M | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Operating Cash Flow | -38.99M | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Investing Cash Flow | 0.00 | 0.00 | 1.21M | 0.00 | 0.00 | -100.00K |
| Financing Cash Flow | 57.15M | 50.02M | 4.19M | 8.98M | 3.79M | 27.61M |
Opus Genetics Technical Analysis
Negative
5.75
Price Trends
4.15
Negative
4.52
Negative
3.40
Negative
Market Momentum
-0.24
Positive
24.65
Positive
6.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRD, the sentiment is Negative. The current price of 5.75 is above the 20-day moving average (MA) of 3.84, above the 50-day MA of 4.15, and above the 200-day MA of 3.40, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 24.65 is Positive, neither overbought nor oversold. The STOCH value of 6.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IRD.
Opus Genetics Risk Analysis
Opus Genetics disclosed 56 risk factors in its most recent earnings report. Opus Genetics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Opus Genetics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $278.59M | -4.13 | -41.31% | ― | ― | 73.45% | |
53 Neutral | $455.40M | -6.66 | -22.51% | ― | 1199.64% | 30.81% | |
53 Neutral | $680.50M | -10.83 | -60.73% | ― | -78.29% | 54.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $269.99M | -2.33 | 6068.79% | ― | -12.22% | 30.28% | |
45 Neutral | $254.96M | -0.54 | 309.79% | ― | -35.61% | -68.92% | |
44 Neutral | $92.54M | -1.48 | -196.72% | ― | ― | 74.83% |
* Healthcare Sector Average
IRD
Opus Genetics
3.05
1.86
156.30%
OVID
Ovid Therapeutics
2.31
1.70
280.99%
STTK
Shattuck Labs
6.82
6.05
785.71%
IKT
Inhibikase Therapeutics
2.23
0.35
18.62%
SRZN
Surrozen
22.16
13.46
154.71%
BMEA
Biomea Fusion
1.31
-0.52
-28.42%
Opus Genetics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Opus Genetics Showcases Expanding Gene Therapy Pipeline Progress
Positive
Jun 16, 2026
On June 16, 2026, Opus Genetics hosted an RD Science Forum to showcase five gene therapy programs for inherited retinal diseases, highlighting three new candidates moving toward the clinic and promising early data from ongoing LCA5 and BEST1 trial...
Business Operations and Strategy
Opus Genetics Highlights Advancing Inherited Retinal Disease Pipeline
Positive
Jun 16, 2026
On June 16, 2026, Opus Genetics hosted a virtual RD Science Forum at which management and external key opinion leaders presented an overview of the company’s clinical pipeline in inherited retinal diseases. The event, available by webcast, h...
Private Placements and Financing
Opus Genetics Secures $155 Million Senior Note Financing
Positive
Apr 24, 2026
On April 2, 2026, Opus Genetics, Inc. entered into a senior secured note purchase agreement allowing for the issuance of up to $155 million in senior secured notes, with $105 million committed by purchasers and $50 million remaining uncommitted. T...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Opus Genetics Shareholders Approve Governance and Capital Changes
Positive
Apr 22, 2026
At its April 20, 2026 annual meeting, Opus Genetics, Inc. stockholders elected nine directors to one-year terms, ratified Ernst Young, LLP as independent auditor for the 2026 fiscal year, and approved on an advisory basis the compensation of the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.